PolarityTE — Investor Presentation (September 2022)
36 slides from PolarityTE's investor presentation, Sep 12, 2022
Slide 1: Investor Presentation September 2022
kj * Investor le Presentation September 2022
Slide 2: Forward looking statement
Se SeF Ser - This presentation contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties and investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Forward-looking statements are no
Slide 3: SkinTE: Highly differentiated, real-world tested asset
SkinTE® Highly differentiated, real-world tested asset with significant market opportunity Phase 3 IND approved Jan 2022 v First pivotal trial — COVER DFUs — commenced enrollment in early Q2 2022 v RMAT Designation Granted May 2022 for DFU and VLU Body of scientific and Real world clinical evidence
Slide 4: Chronic Wounds: A large and growing health and economic problem
6.5M Affected Patients in the US per year ~2.4M Annual Incidence Rate of DFUs ~2.5M Annual Incidence Rate of Pressure Injury Chronic Wounds A large and growing health and economic problem Types of Chronic Wounds Diabetic Foot Ulcers Venous Leg Ulcers Pressure Injuries More than Chronic wounds are $2
Slide 5: SkinTE for Diabetic Foot Ulcers represents a significant commercial opportunity
34M Diabetics in the United States? 2.2M DFU Annual Incidence Rate* SkinTE® for Diabetic Foot Ulcers represents a significant commercial opportunity Current products and Trials are Largely Focused on Wagner 1 DFUs and Primarily in the Outpatient Setting of Care! 75% of actual wound ~46% of DFUs 160K
Slide 6: Why Wagner 2 and 3?
Why Wagner 2 and 3? Because the most severe Diabetic Foot Ulcers are the true need. Need for Treatments with Clinical Versatility Across Settings of Care CDC reports 130K yearly amputations and 80% were attributed to the 160K inpatient population with diabetic foot ulcer diagnosis.34 22.7% of Wagner
Slide 7: SkinTE is designed to address limitations of current treatments
—_—-— a Sob == _— ~ Current treatments are not sufficient for true healing SkinTE® is designed to address limitations of current treatments PRODUCT LIMITATIONS SKINTE® ATTRIBUTES Mimic dermal component of skin with no epidermis Autologous and engrafts contributing Skin Substitutes Rely on wound bed
Slide 8: SkinTE: A new approach to hard-to-heal chronic and acute wounds
SkinTE® A new approach to hard-to-heal chronic and acute wounds of deep wounds and —_ Closure from the Application in a exposed structures * —_— — F inside out single visit in any | setting of care | Treatment Results in Fully Functional Skin SkinTE® is Available for Investigational Use Only Que
Slide 9: Available for Investigational Use Only
Available for Investigational Use Only
Slide 10: Regenerative potential of skin
Regenerative potential of skin FOLLICULAR BULGE CELLS ADIPOSE DERIVED CELLS
Slide 11: Limits of endogenous healing
Limits of endogenous healing We ate Ay’
Slide 12: Goals of therapy
Goals of therapy >) Epithelium that prevents bacterial penetration and retains moisture >) Dermis that is durable yet flexible >) Dermal appendages that facilitate moisture and thermal regulation and sensation © 2022 PolarityTE, Inc.All Rights Reserved. For Investors Only. Not For General Distributi
Slide 13: Development of SkinTE: Address Limitations of Existing Treatments
Development of SkinTE®—Address Limitations of Existing Treatments Epidermis EPIDERMAL ~< CELLS ot FOLLICULAR BULGE CELLS Single-Cell Suspension ADIPOSE DERIVED
Slide 14: SkinTE Autologous Heterogeneous Skin Construct (AHSC)
SkinTE® Autologous Heterogeneous Skin Construct (AHSC) Multicellular segments with endogenous cellular skin populations including keratinocytes, fibroblasts, endothelial cells, follicular cells, and extracellular matrix Not cultured ex vivo - engrafts and expands in the wound bed Multicellular segme
Slide 15: Engraftment of healthy autologous SkinTE multicellular segments
Engraftment of healthy autologous SkinTE multicellular segments Mechanism of action Developed through extensive in vitro and in vivo research and testing Proliferation and SkinTE expresses growth factors, migration of the SkinTE cytokines, and extracellular matrix cellular populations supporting the
Slide 16: SkinTE process & QA release testing
SkinTE® process & QA release testing Purity Identity Potency SkinTE is manufactured SkinTE is tested to ensure it SkinTE is tested to aseptically and is tested for has the necessary epidermal and ensure cellular viability bacterial contamination dermal cellular components and cellular activation Ski
Slide 17: Closure — not contracture — from the inside out
Closure — not contracture — from the inside out >) SkinTE Progression of Closure and Remodeling of a 200 cm2 Wound Over 13 Months? Punch Biopsy of a region treated with SkinTE — six months following deployment with Highlighting Rete Pegs’ HYPODERMIS correlative histology’ © 2022 PolarityTE, Inc.All
Slide 18: SkinTE Published clinical data
SkinTE® Published clinical data = BRS 5 ORIGINAL ARTICLE: | Reconstructive. Sie Openabel Venous Leg Ulcer Pilot Study Using a Regeneration of Functional, Full-Thickness Novel Autolologous Homologous Skin Construct erty a wiey A multicentre, randomised controlled clinical trial ‘evaluating the effect
Slide 19: SkinTE DFU Randomized Controlled Trial (RCT)
SkinTE® DFU Randomized Controlled Trial (RCT) Statistically Significant Results 70% Closure with AHSC Primary Endpoint Closure at 12 Weeks AHSC 35/50 (70%) Closed soc 17/50 (34%) Closed p=0.00032 GREATER PAR with AHSC Secondary Endpoint Increased Percent Area Reduction (PAR) at 4, 6, 8, 10 and 12 We
Slide 20: SkinTE Venous Leg Ulcer RCT
SkinTE® Venous Leg Ulcer RCT Statistically Significant Results ™M% Closure with AHSC Primary Endpoint Closure at 12 Weeks AHSC 10/14 (71%) Closed soc 5/15 (33%) Closed p=0.046 GREATER PAR with AHSC Secondary Endpoint Increased Percent Area Reduction (PAR) at 4, 6, 8, 10 and 12 Weeks p=0.000035 93% S
Slide 21: SkinTE for Complex Diabetic Foot Ulcers
SkinTE® for Complex Diabetic Foot Ulcers © Success in closing DFUs in randomized controlled trial and real-world evidence2!2 © 2022 Polarity, Inc.All Rights Reserved. For Investors Only. Not For General Distribution, DFU Outcomes from Pilot Trial? Initial wound ~9 weeks after single application of S
Slide 22: DFU Phase III Pivotal Trial Timeline
SkinTE® DFU Phlll Pivotal Trial Timeline RMAT Designation Received April 2022 Diabetic Foot Ulcers Ji 2022 2 2022 3/Q4 2023 2/Q3 2024 First Phill - Wagner 2 came 2 ea ore Aiming to commence study in Diabetic Foot Ulcers early 2023. Timing, size and January 2022 a a Second Phlll — Wagner 3 duration i
Slide 23: SkinTE Pipeline
SkinTE® Pipeline Product SkinTE SkinTE POC SkinTE Cryo Indication / Application Other Chronic Wounds (ex. Pressure Injuries, Venous Leg Ulcer) Acute/Traumatic Wounds Burns Point-of-care device for on-site SkinTE processing and deployment Cryopreservation of SkinTE for multiple deployments on a singl
Slide 24: SkinTE for Pressure Injury
SkinTE® for Pressure Injury g J ty Initial wound ~11 weeks after ~23 weeks after >) Real world evidence supports proof single application single application i ini of SkinTE of SkinTE of concept in pressure injury 22 23 Sacral Pressure Injury’ >] Only 30% of stage IV ulcers heal within 6 months with
Slide 25: SkinTE shows success for additional treatments
SkinTE® shows success for additional treatments ~84K TRAUMA CASES per year 26 SkinTE has been successfully deployed in clinical use for acute traumatic wounds \ Initial wound ~11 weeks after ~16 weeks after SkinTE SkinTE ~42K BURN CASES per year applicable for SkinTE Initial wound SKINTE FOR BURNS S
Slide 26: Management team with deep operational, clinical, and R&D experience
Management team with deep operational, clinical, and research and development experience a ae Sy ww 7 Z 7 s Richard Hague Jacob Patterson Nikolai Sopko, Ryan Mathis, Kolby Day, JD Chief Executive Chief Financial Officer MD, PhD MD Senior Vice President GificeriatPrasident Chief Scientific Officer Ch
Slide 27: Board of directors
Peter Cohen, MBA Chairman of the Board & Chairman of Compensation Committee + Former Board Member of the NYSE + Former Chairman of Shearson Lehman Hutton, Inc. + Former Chairman and CEO of Cowen Inc. + Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation + Federa
Slide 28: Poised for success with a novel and proven technology
Poised for success with a novel and proven technology BUILDING THE FOUNDATION IND Approved & RMAT Designation Granted SkinTE IND Accepted for Chronic Cutaneous Ulcers; First Phase 3 Clinical Trial in Wagner 2 DFUs Commenced in Q2 2022; RMAT Designation Granted in Q2 2022 ~1,200 Clinical Cases Focuse
Slide 29: Slide 29
Slide 30: PolarityTE
io) PolarityTE
Slide 31: PolarityTE History
9 Founded in 2016 by MD/PhD from Johns Hopkins “oe? Autologous cell & tissue technology platform for skin regeneration ns SkinTE® was previously marketed as 361 HCT/P— 1,200 patients treated r Pivoted to 351/BLA pathway—off market as 361 HCT/P in May 2021 after end of enforcement discretion Polarity
Slide 32: Peer reviewed publications
Peer reviewed publications ‘A multicentre, randomised controlled clinical trial evaluating the effects of a novel 8. "What to put on (and what to take off) a wound: treating a chronic neuropathic ulcer autologous, heterogeneous skin construct in the treatment of Wagner one diabetic with an autologou
Slide 33: Activation of wound healing pathways
Activation of wound healing pathways Gene Expression Gene Expression Mass Spectrometry Array Stem Cell Array Extracellular Protein Profiling Pathways Matrix Pathways
Slide 34: Extensive in vivo research and testing
Extensive in vivo research and testing Xenograft Mouse Model Advanced Dressing SkinTE Swine Models swas35 AS 36 cm2 full-excisional wounds Arms: Dressing vs SkinTE + Dressing SWa535 AZ SW8535 AS SkinTE 1:36 expansion ratio rosie
Slide 35: References
References 1. Sen, Chandan K. “Human Wounds and Its Burden: An Updated Compendium of Estimates.” Advances in wound care vol. 8,2 (2019): 39-48. doi:10.1089/wound.2019.0946 2. Armstrong, David G et al. “Complete wound closure following a single topical application of a novel autologous homologous ski
Slide 36: References (continued)
References (continued) 18 VanGilder C, Macfarlane GD, Meyer S. Results of nine international pressure ulcer prevalence surveys: 1989 to 2005. Ostomy Wound Manage. 2008;54(2):40-54. 19. Bates-Jensen BM, Guihan M, Garber SL, Chin AS, Burns SP. Characteristics of recurrent pressure ulcers in veterans w